Effects of Oxyfedrine and Ouabain on the Heart-lung Preparation of the Dog

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1973 Jan 1

PMID 4267600

Citations 1

Authors

K Sakai

S Sugano

C ISONO

Affiliations

Soon will be listed here.

Citing Articles

Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.

Bagardi M, Zamboni V, Locatelli C, Galizzi A, Ghilardi S, Brambilla P Animals (Basel). 2022; 12(2).

PMID: 35049831 PMC: 8773235. DOI: 10.3390/ani12020209.

References

Thiele K, Schimassek U, VON SCHLICHTEGROLL A . [New cardioactive beta-aminoketones. Synthesis and considerations on the relationships between pharmacologic effect and constitution of new Mannich bases. I]. Arzneimittelforschung. 1966; 16(8):1064-7. View

Walker J, LOURIE E, BURN J . The effects of digoxin and ouabain on the heart-lung preparation of the dog. Br J Pharmacol Chemother. 1950; 5(2):306-14. PMC: 1509984. DOI: 10.1111/j.1476-5381.1950.tb01015.x. View

WOLLENBERGER A . On the energy-rich phosphate supply of the failing heart. Am J Physiol. 2010; 150(4):733-45. DOI: 10.1152/ajplegacy.1947.150.4.733. View

Moll A, PETZEL H . [Experimental and clinical studies with a new coronary and heart-active substance]. Z Kreislaufforsch. 1967; 56(1):46-58. View

Kukovetz W, Poch G . [Stimulation of adrenergic beta-receptors in the heart of normal and reserpinized guinea pigs by oxyfedrine]. Arzneimittelforschung. 1969; 19(9):1562-6. View

Chidsey C, Braunwald E . Sympathetic activity and neurotransmitter depletion in congestive heart failure. Pharmacol Rev. 1966; 18(1):685-700. View

Epstein S, Braunwald E . Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. N Engl J Med. 1966; 275(20):1106-12 contd. DOI: 10.1056/NEJM196611172752006. View

SARNOFF S, Berglund E . Ventricular function. I. Starling's law of the heart studied by means of simultaneous right and left ventricular function curves in the dog. Circulation. 1954; 9(5):706-18. DOI: 10.1161/01.cir.9.5.706. View

Farah A . The determination of the minimal lethal dose and the average rate of uptake of G-strophantin and digitoxin in the heart-lung preparation of the dog. J Pharmacol Exp Ther. 2010; 86:101-12. View

10.

Imai S, SHIGEI T, Hashimoto K . Cardiac actions of methoxamine with special reference to its antagonistic action to epinephrine. Circ Res. 1961; 9:552-60. DOI: 10.1161/01.res.9.3.552. View

11.

Sakai K . Beta-adrenergic blocking property of l-3-methoxy-omega-(1-hydroxy-1-phenylisopropylamino)-propiophenone-HCL (D 563) in femoral circulation. Jpn J Pharmacol. 1970; 20(2):306-7. DOI: 10.1254/jjp.20.306. View

12.

Stephen S . Unwanted effects of propranolol. Am J Cardiol. 1966; 18(3):463-72. DOI: 10.1016/0002-9149(66)90071-3. View

13.

LEDINGHAM I, McArdle C, Parratt J . Proceedings: Comparison of a coronary vasodilator drug (carbochromen) and a cardiac stimulant (oxyfedrin) on blood flow and oxygen extraction in experimental myocardial infarcts. Br J Pharmacol. 1972; 44(2):323P-324P. PMC: 1666074. DOI: 10.1111/j.1476-5381.1972.tb07273.x. View

14.

VICK R, KAHN Jr J, ACHESON G . Effects of dihydro-ouabain, dihydrodigoxin and dihydrodigitoxin on the heart-lung preparation of the dog. J Pharmacol Exp Ther. 1957; 121(3):330-9. View

15.

Sakai K, Sugano S, Watanabe I, Fukushima M, Takanashi S, Nishii Y . Metabolism of oxyfedrine. Naunyn Schmiedebergs Arch Pharmacol. 1972; 275(3):323-37. DOI: 10.1007/BF00500060. View

16.

Somani P, Laddu A . Blockade of cardiac effects of isoproterenol by 4-(2-hydroxy-3-isopropylaminopropoxy)-acetanilide (ICI 50,172). J Pharmacol Exp Ther. 1969; 170(1):72-8. View

17.

Farah A, Maresh G . Determination of the therapeutic, irregularity, and lethal doses of cardiac glycosides in the heart-lung preparation of the dog. J Pharmacol Exp Ther. 1948; 92(1):32-42. View

18.

Bosse J, Schaum E . [Studies on the mechanism of action of INPEA, iproveratril and oxyfedrin]. Naunyn Schmiedebergs Arch Pharmakol. 1969; 264(3):221-2. View

19.

STERNITZKE N, Kohler J, Lang E . [The effect of ildamen, a cardio-energetic coronary therapeutic agent, on cardiovascular dynamics]. Med Welt. 1966; (36):1910-5. View

20.

Greif S, LIERTZER V . [The management of angina pectoris using Ildamen, a new coronary- and cardiac-active substance, in a double-blind study]. Arztl Forsch. 1967; 21(9):354-8. View